Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R L Woosley

Showing results (1-10 of 201) with videos related to

Pageof 21
Sort By:
Clinical Pharmacology and Therapeutics|March 21, 2013
It is important research, but why is it necessary?R L Woosley
Cardiovascular Drugs and Therapy|June 1, 1990
New concepts affecting the use of antiarrhythmic agentsR L Woosley
JAMA|December 21, 2000
Drug labeling revisions-guaranteed to fail?R L Woosley
Clinical Pharmacology and Therapeutics|February 21, 2012
Is it possible for FDA regulatory scientists and industry scientists to work together?R L Woosley
American Heart Journal|November 1, 1987
Pharmacokinetics and pharmacodynamics of antiarrhythmic agents in patients with congestive heart failureR L Woosley
Rational Drug Therapy|March 1, 1987
Mexiletine and tocainide: a profile of two lidocaine analogsR L Woosley
Issues in Science and Technology|January 3, 1995
A prescription for better prescriptionsR L Woosley
Annual Review of Pharmacology and Toxicology|January 1, 1991
Antiarrhythmic drugsR L Woosley
Annual Review of Pharmacology and Toxicology|January 1, 1996
Cardiac actions of antihistaminesR L Woosley
JAMA|July 4, 1986
Risk/benefit considerations in antiarrhythmic therapyR L Woosley
Pageof 21

Showing results (1-10 of 201) with videos related to

Sort By:
Pageof 21
Clinical Pharmacology and Therapeutics|March 21, 2013
It is important research, but why is it necessary?R L Woosley
Cardiovascular Drugs and Therapy|June 1, 1990
New concepts affecting the use of antiarrhythmic agentsR L Woosley
JAMA|December 21, 2000
Drug labeling revisions-guaranteed to fail?R L Woosley
Clinical Pharmacology and Therapeutics|February 21, 2012
Is it possible for FDA regulatory scientists and industry scientists to work together?R L Woosley
American Heart Journal|November 1, 1987
Pharmacokinetics and pharmacodynamics of antiarrhythmic agents in patients with congestive heart failureR L Woosley
Rational Drug Therapy|March 1, 1987
Mexiletine and tocainide: a profile of two lidocaine analogsR L Woosley
Issues in Science and Technology|January 3, 1995
A prescription for better prescriptionsR L Woosley
Annual Review of Pharmacology and Toxicology|January 1, 1991
Antiarrhythmic drugsR L Woosley
Annual Review of Pharmacology and Toxicology|January 1, 1996
Cardiac actions of antihistaminesR L Woosley
JAMA|July 4, 1986
Risk/benefit considerations in antiarrhythmic therapyR L Woosley
Pageof 21